Specific anti-SARS-CoV-2 humoral and cellular responses
To analyse the participant´s serological response, a blood draw was performed 10 and 20 weeks after entering the clinical trial. Anti-SARS-CoV-2 antibody detection was performed using four commercial chemiluminescence tests. First, quantification of total antibodies (IgG+IgM) against the receptor binding domain of SARS-CoV-2 spike (S) using ElecsysCell-mediated immune response to SARS-CoV-2 was measured using QuantiFERON